Automated Dialysis vs Daily Dialysis for End-stage Kidney Disease
Comparative Study of Prognosis and QOL Between APD-RPM and CAPD
Recruiting
Observational Study
End-stage Renal Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Observational
- Participants needed
- 750 (estimated)
- Sponsor
- Chinese PLA General Hospital · Other
Who this trial is looking for
This trial is looking for patients with end-stage kidney disease to compare two types of dialysis treatments. Participants will need to attend follow-up visits every 12 weeks for about 3 years.
Are You a Good Fit for This Trial?
You may be able to join if
- I am between 18 and 75 years old.
- I have end-stage renal disease.
- I can follow the required dialysis treatment at home.
- I have been receiving peritoneal dialysis for at least 3 months.
- I understand the study and have signed consent.
You may not be able to join if
- I plan to have a kidney transplant in the next 3 years.
- I need hemodialysis treatment as well.
- I am allergic to peritoneal dialysis fluid.
- I have serious heart or brain diseases.
- I have severe liver disease.
- I have active cancer or HIV.
- I am pregnant or breastfeeding and won't use birth control.
- I have had peritonitis in the past 3 months.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is an observational, multicenter, parallel control study, planning to enroll 750 eligible patients to receive automated peritoneal dialysis with remote patient management (APD-RPM) and continuous ambulatory peritoneal dialysis (CAPD). Patients will attend follow-up every 12 ± 1 weeks for a total of 156 weeks. This study aims to compare the effects of APD-RPM and CAPD treatment on the prognosi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Aged 18 years to 75 years
* Confirmed diagnosis of end-stage renal disease
* Standard peritoneal balance test shows rapid peritoneal solute transfer rate, defined as 4 hours D/P creatinine value greater than 0.65
* Be able to comply with the standard peritoneal dialysis treatm…
Contacts